LATIFY Trial

No OCR text available for this slide group.

[Slide 1] LATIFY study design Phase 3, randomised, open-label, multicentre study (NCT05450692) Primary endpoint Key eligibility os Secondary endpoints included: Locally advanced/metastatic Ceralasertib 240 mg PO BID Days 1-7 PFS$ NSCLC without actionable Durvalumab 1500 mg IV on Day 8 Q28D ORR elcc genomic alterations* N=594 (N=299) DoR$ OS at 12 months Eligible for 2L or 3L treatment R PROs following progression on or after 1:1 Safety platinum-based CT and anti-PD-(L)1 therapy Stratified by (concurrent or sequential) Histology (squamous vs non- squamous) Docetaxel 75 mg/m² IV on Day 1 Q21D os and PFS in key subgroups Resistance to prior andi-PD-(L)1 therapy (N=295) ATM protein (<25%/225%) Documented PD-L1 status! (primary in acquired? ATM afteration presence absence)** PD-L1 status (YTN is 21%) Histology (squamous non-equamous) ECOG/WHO PS 0 or 1 Descraphical region North America and Western Europe is PD-L1 expression (<1% 1-49% >50%) other peographical regions) Resistance to prior and PD-(L)1 therapy (primary acquired) TGR and ALK widhge no the ROST RET MET BRAF V000 NTRKY and NTRQ stations Per VENTANA POL (SP283) many Presery resistence NON defined is Income progression 575 form start of peor - PD-(L)1 treatment and acquired resistance - docase progression vss - from the start of por and instruct Unvestgabe assessed per RECIST in the protest expressen - evaluated - he Ventana Y170 many if pro- delined of - (425% total in 925% normal) a unknown) "ATM derations - defend by combining AIM Issue mutstion BONAATM mutation - and ATM protest repression ATM mutations were classified - Intected (dditional or suspected felebrious) not detected NO pathoginic mutations - heAlth one) - unknown a ascend the 1. ALK yephone - ADM Alamis mutal no be day CT, chemotherapy MONA circulating know ONA DeR duration of response E000 Dooperative Group EGFR epidemal growth factor mapler N intravenously ORR response rate OS, overst survive PES progression free survival PO only PROM policed reported outsomes PS performance Q210 every 21 tays COSO every a Says, R condomized RECIST of 1. Response valuation Criteria a Sold Tunors verson 11 WHO Mind Health Organization elcc European Lung Cancer Congress 2026 --- [Slide 2] Conclusions LATIFY did not meet its primary endpoint, ceralasertib + durvalumab did not demonstrate a statistically significant improvement in OS compared with docetaxel - OS HR = 0.90 (95% Cl: 0.75-1.09; p = 0.287); median OS was 11.1 months (95% Cl: 10.0-12.7) in the ceralasertib + durvalumab arm VS 10.0 months (95% Cl: 8.5-11.7) in the docetaxel arm PFS and ORR were also not improved with ceralasertib + durvalumab VS docetaxel - Median PFS was 4.1 months (95% Cl: 3.8-4.4) in the ceralasertib + durvalumab arm VS 4.1 months (95% Cl: 3.5-4.3) in the docetaxel arm - ORR was 7.7% (95% Cl: 4.9-11.3) in the ceralasertib + durvalumab arm VS 17.3% (95% Cl: 13.2-22.1) in the docetaxel arm OS and PFS were generally consistent across prespecified subgroups - In LATIFY, ORR, PFS, and OS among patients with ATM alterations did not replicate the clinical activity observed in HUDSON Ceralasertib + durvalumab was tolerable and AEs were consistent with the known safety profiles of each agent --- [Slide 3] Secondary endpoint: Progression-free survival 1.0 Ceralasertib + Docetaxel durvalumab (n=299) (n=295) 0.8 Events, (%) 262 (87.6) 236 (80.0) mPFS, months (95% CI) 4.1 (3.8-4.4) 4.1(3.5-4.3) HR (95% CI) 0.87 (0.73-1.04) 0.6 Nominal p-value 0.133 Extramenting Probability of PFS Median duration of follow-up in 16.6 (0-31) 0.8 (0-29) elcc censored patients, months (range) 0.4 0.2 0 0 3 6 9 12 15 18 21 24 27 30 33 No. at risk Time from randomisation (months) Certificate 200 176 98 56 43 34 24 0 2 1 1 0 ourvalured Docetased 295 151 01 a 10 13 11 5 3 1 0 0 Data a October 00. 2025 Tick marks indicate consored data The 95% Cla for mPFS were calculated using the Brookneyer Crowdey method The HR and associated 95% Cla were calculated from a strattlied Cox proportional hazands model mPFS median progression- the service elcc European Lung Cancer Congress 2026 --- [Slide 4] Primary endpoint: Overall survival 1.0 Ceralasertib + Docetaxel durvalumab (n=299) (n=295) 0.8 Events, (%) 214(71.6) 219 (74.2) mOS, months (95% CI) 11.1(10.0-12.7) 10.0 (8.5-11.7) HR (95% CI) 0.90 (0.75-1.09) elcc Probability of os 0.6 p-value 0.287 Median duration of follow-up in 19.9 (0-32) 19.5(0-31) 40.2% - censored patients, months (range) 0.4 43.0% 0.2 0 0 3 6 9 12 15 18 21 24 27 30 33 No. risk Time from randomisation (months) Certificate 200 258 202 100 durvalurnab 127 101 11 43 22 9 5 0 Doortased 255 234 185 145 110 97 78 47 24 11 1 0 Date a October 06, 2025 Tick marks indicate ownered date The 95% Chs for nos were calculated wing the Brookmeyer Crewtity method The HR and associated 95% Ch were calculated tom straided Cox perportional hazanda model The significance level by testing os at his final analysis - 4. 15% 2 sided) at the oversl 4. 90% level allowing for strong elpha control across interm and trat analysis Imports nos median overal survival elcc European Lung Cancer Congress 2026

No OCR text available for this slide group.

No OCR text available for this slide group.

No OCR text available for this slide group.